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Introduction:  Despite  good  clinical  results  following  total  ankle  replacement  (TAR), the  development  of
large periprosthetic  cysts  (>  400  mm2) in  the  medium-term  is  a source  of  concern.
Objective:  The  primary  objective  of  this  study  was  to detect  any  large  periprosthetic  cysts  in  a  cohort  of
AKILETM patients  using  radiographs  and CT  scans,  and  then  to  compare  these  ﬁndings  to published  ones.
Material  and methods:  A  total  of  127  TAR  procedures  were  performed  between  June 1995 and  January
2012.  We  retrospectively  reviewed  68  cases  with  the  newest  AKILETM implant  design  that  had  a  minimum
follow-up  of  36  months.  The  average  follow-up  was  81  ± 33 months;  eight  patients  were  lost  to  follow-up.
The  outcomes  consisted  of analyzing  radiographs  (A/P and lateral  weight  bearing  views, Meary view and
lateral  views  of  ﬂexion/extension)  and  helical  CT scans,  performing  clinical  evaluations  (range  of motion,
AOFAS  score,  Foot  Function  Index,  pain  levels)  and  determining  the  survivorship  of TAR  implants.
Results:  TAR  survival  at 5 years  was  79%  for  in  situ implants  and  62%  for  revision-free  implants.  The  AOFAS
score  improved  from  33.7 ± 14.7  to 77.1  ± 15.1  (out  of  100)  and  the pain  sub-score  was  30.2  ± 9.7 (out
of  40) at the last follow-up.  The  average  ankle  range  of motion  was  32.3◦ ±  12.7◦ on  the radiographs.  CT
scan  revealed  Type  A  cysts (< 200  mm2) under  the talar  implant  in 52%  of  cases  and  in the  tibia  in 50%
of  cases;  these  cysts  were  smaller  than  100 mm2 in  80%  of cases  and  had  no effect  on  the  implants.  No
periprosthetic  cysts  larger  than 400  mm2 in size  were  identiﬁed.
Discussion:  The  medium-term  functional  results  and  survivorship  are  comparable  to  those  reported  for
other  TAR  designs.  The  incidence  of  cysts  was  low  overall  and  there  were  no  large-diameter  cysts,  which
should  improve  long-term  survival.  The  implant’s  design  and  materials  likely  played  a  role  in  preserving
the  periprosthetic  bone  stock.  The  AKILETM TAR  has  distinctive  features  related  to  the  low  rate  of  large
periprosthetic  cysts  in the  medium-term.
Level  of evidence:  IV (retrospective  case  series).
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
The functional beneﬁts of mobile-bearing total ankle replace-
ent (TAR) implants in the medium-term are signiﬁcant [1,2]. But
eriprosthetic osteolysis and cysts in the medium and long-term
re a source of concern and temper the excellent short-term results
3]. In some studies, the rate of radiolucent lines and cysts has
eached 75%, with large cysts compromising implant stability [4–6].
he primary objective of the current study was to analyze the radio-
raphic results in a cohort of existing AKILETM TAR by looking for
he presence of bone cysts and evaluating their size on CT scans. The
∗ Corresponding author.
E-mail address: julien.lucas@chu-bordeaux.fr (J. Lucas y Hernandez).
http://dx.doi.org/10.1016/j.otsr.2014.09.019
877-0568/© 2014 Elsevier Masson SAS. All rights reserved.secondary objective was  to determine the clinical results and com-
pare them to published results. Only patients who  had undergone
TAR with the newest AKILETM implant design were reviewed.
2. Material and methods
2.1. Study design
This was  a retrospective study of the AKILETM TAR procedures
performed by the surgeon designers (DC and OL, Bordeaux Univer-
sity Hospital) between June 1995 and January 2012. The inclusion
criteria consisted of primary, post-traumatic or inﬂammatory ankle
arthritis as graded by Morrey and Wiedemann [7], which had failed
conservative treatment and had at least 10◦ range of motion with no
equinus deformity. Exclusion criteria consisted of greater than 10◦
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other surgeon (OL) did not. A locking tibial keel was  added in cases
where the surgeon’s intra-operative assessment of bone quality led
to doubts about the hold of the tibial component.Fig. 1. Study design; TAR: total an
isalignment of the hindfoot, insufﬁcient bone stock, signiﬁcant
isk to the skin, morbid obesity and poor peripheral vasculariza-
ion. Although 127 TAR procedures were carried out during that
ime period, the clinical and radiology analyses were performed on
nly the patients who received the newest implant design and had
t least 36 months of follow-up.
.2. Patient series
The cohort consisted of 68 cases in 66 patients (41 men, 25
omen) having an average age of 57 ± 12.2 years (range 26–77)
t implantation; nine patients were lost to follow-up (LTF) and one
ad died before the last follow-up (Fig. 1). The average follow-up
as 81 ± 33.3 months. The arthritis etiology was traumatic in 40
ases, primary in 11 cases and inﬂammatory in 17. Ten ankles were
rade 1, 34 were Grade 2 and 24 were Grade 3 based on the Mor-
ey and Wiedeman classiﬁcation (Grade 0: normal ankle, Grade 1:
mall osteophytes and minimal joint narrowing, Grade 2: moder-
te osteophytes and moderate joint narrowing, Grade 3: signiﬁcant
arrowing with joint deformation or fusion) [7]. The TAR procedure
as performed on the left ankle in 35 cases (51.5%) and the right
nkle in 33 cases (48.5%). The implant’s modular design allowed the
urgeon to determine if a tibial keel and/or cement were needed on
 case by case basis (Fig. 2).
ig. 2. Use of cement and tibial keel in the various implantations; C = cemented
mplant.placement, LTF: lost to follow-up.
2.3. Implant and surgical technique
The newest AKILETM prosthesis is a third-generation, spheri-
cal trochlear resurfacing implant with a high-molecular weight
polyethylene (PE) mobile-bearing. It is made up of three com-
ponents: a spherical tibial component, a trochlear-shaped talar
component and a dual-curvature PE insert (Fig. 3). The tibial and
talar components are made of ultra-strong high nitrogen stainless
steel (ISO 5832-9). The surfaces in contact with the PE are coated
with a diamond-like carbon material (CarbioceramTM). This coating
reduces the coefﬁcient of friction of the metal surfaces and helps
minimize PE debris [8–10]. An anterior approach was used in all
cases and an additional tibial bone ﬂap was used in cases where a
tibial keel was implanted. Cementing of the implants was optional;
one surgeon (DC) cemented all the talar components while theFig. 3. The various components of the AKILETM total ankle arthroplasty implant.
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The following additional procedures were performed:
8 percutaneous pie-crust lengthening of the Achilles tendon,
 subtalar fusion and 2 varus osteotomy of the calcaneus (carried
ut 3 weeks before the TAR). Weight bearing was  not allowed
uring the ﬁrst 4 weeks after surgery so as to maximize bone
ntegration of the alumina surfaces; rehabilitation was  initiated
fterwards.
.4. Outcome measures
.4.1. Radiological
Weight bearing radiographs (A/P, lateral, Méary view) were per-
ormed before the surgery and at every follow-up visit. Dynamic
eight bearing radiographs in maximum ankle ﬂexion and exten-
ion were performed before the surgery and at the last follow-up
isit to evaluate the joint’s range of motion. Helical CT scan was  per-
ormed in all patients at the last follow-up visit. All of these images
ere reviewed by two independent evaluators (ET, JL).
.4.1.1. Implant positioning. Implant positioning was evaluated
hrough the following criteria: alpha angle between horizontal axis
f tibial component and tibial axis (normal value of 90◦ ± 5), beta
ngle between the sagittal axis of the tibial component and the tib-
al axis (normal value of 86◦ ± 5) and gamma  angle between the axis
f the talar component and the ground (normal value of 0◦ ± 5). The
ibial axis was deﬁned as a line passing through the centre of the
ibial shaft and the centre of the ankle mortise (Fig. 4).
.4.1.2. Bone-implant interface. Analysis of abnormal bone appear-
nce was performed according to the 10-zone joint map  and
rotocol described by Besse et al. [4] (Fig. 5). The appearance
as deﬁned as either normal (N: 0 mm),  with radiolucent lines
L: 0–2 mm),  or the presence of cystic lesions with size measured
n mm:  A (3–5 mm),  B (5–10 mm),  C (10–20 mm),  D (20–30 mm),
nd E (more than 30 mm).  Five additional areas were deﬁned and
nalyzed on the CT scans; the volume of any cysts was  measured
n mm2 (maximum area on the sagittal or coronal plane) using
SIRIXTM software. These measurements were used to classify theition on plain radiographs.
cysts into three groups: A (0–200 mm2) B (200–400 mm2), C (more
than 400 mm2) [11]. Group A was divided in four sub-groups to
reﬁne the analysis of small cysts (Fig. 6).
2.4.2. Clinical and functional
Follow-up visits were scheduled for 1, 6 and 12 months
post-surgery and then annually. Functional and clinical outcome
measures (AOFAS score, joint range of motion and Foot Func-
tion Index [FFI]) were taken before the surgery and at the last
follow-up [12,13]. Any postoperative complications were classiﬁed
according to Glazebrook et al. [14]. Any re-operations on the ankle
were noted.
2.5. Data analysis
Statistical analysis was performed using Student’s or Welch’s
test for paired samples to compare pre- and postoperative data;
the chi-squared test was used to determine if a relationship existed
between variables. Kaplan-Meier survival curves were calculated
by deﬁning full revision (or removal) of the implant and a new
surgical procedure as the end point for all patients. To determine
if there was  a learning effect, another set of survival curves was
calculated with non-revised implants (new surgical procedure as
end point) by comparing the ﬁrst 30 TAR procedures in the initial
127 patient cohort with the last 30 TAR procedures having at least
3 years of postoperative follow-up. A threshold of P < 0.05 was used
to determine statistical signiﬁcance in all of the tests. The statistical
analysis was  performed with the XLstat software (Addinsoft, Paris,
France).
3. Results
At the last follow-up, 51 of the 68 TAR implants were still in
place (in situ). The 5-year survivorship was 79.4% [71.9–87.0] for
in situ TAR implants and 62% [52.9–71.2] for non-revised implants
(Fig. 7). The 3-year revision-free survival was 56.7% [38.9–74.4] for
the ﬁrst 30 cases and 77.4% [62.7–92.1] for the last 30 cases (Fig. 8).
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.1. ComplicationsIntra-operative and postoperative complications (Table 1) were
lassiﬁed according to a modiﬁed Glazebrook classiﬁcation. Two
roups were added: idiopathic residual pain as a high-grade
omplication and implant impingement (mainly in the grooves)
Fig. 6. The 10 areas used to deﬁne the location of bone cysts on CT scans.hs using the ﬁve areas deﬁned by Besse.
as a medium-grade complication. Thirteen cases had to be revised
with an arthrodesis procedure; all had fused at the last follow-up
and the average AOFAS score had improved from 45.4 [17–49] to
65.6 [25–69]. Of the ﬁve arthrodesis procedures performed because
of idiopathic pain, only three patients experienced complete pain
relief after the fusion.
3.2. Clinical and functional outcomes
The functional outcomes (AOFAS Hindfoot and Ankle Scale)
improved from an average of 33.7 ± 14.7 [7–77] before the surgery
for all implants to 77.1 ± 15.1 [25–98] at the last follow-up for the
51 in situ implants. For these 51 implants, the average FFI score
was 101.2 ± 36.2 (out of 209) [40–179] and the average AOFAS pain
score was  30.2 ± 9.7 (out of 40) [0–40]. In 13 of these 51 cases, the
pain score was  less than 30.
Average range of motion before the surgery was 23.6◦ ± 9.7◦
[10◦–60◦] including 4.9◦ ± 4.2◦ [0◦–35◦] of dorsiﬂexion. After the
surgery, the range of motion was  29.7◦ ± 11.6◦ [15◦–60◦] including
5.6◦ ± 5.8◦ [0◦–20◦] of dorsiﬂexion (P > 0.05).
3.3. Radiological outcomes
Plain radiographs were taken in all the patients during the
follow-up period.
Djian’s quadrilateral was measured on the Méary views. The
average valgus deformity was  3.7◦ ± 3.2 [−5◦ to 10◦] before the
surgery and 3.5◦ ± 3.0 [−5◦ to 10◦] at the last follow-up. The ankle
range of motion at the last follow-up was  32.3◦ ± 12.8◦ [10◦ to 60◦]
(Fig. 9). The location of cysts was deﬁned using the Besse zones
(Table 2) and their volume and quantity were measured (Table 3)
[4].
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Fig. 7. In situ implant survival curve (left) and revision-free survival curve (right).
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CT scans were performed in 42 implants (97.7% of in situ
mplants) at the last follow-up (Fig. 1) to more speciﬁcally ana-
yze the bone-implant interface. Ten of the CT scans had no signs of
steolysis; 28 (67%) had Type A images (< 200 mm2). Only four (9%)
ad a signs of Type B osteolysis (200–400 mm2); these were asso-
iated in 50% of cases to another Type A image. This osteolysis was
ocated at the cemented tibial component in three cases. The talar
mplant showed no signs of migration; the cysts identiﬁed were
08, 346 and 244 mm2 in size, respectively, in CT scans performed
able 1
omplications based on a modiﬁed Glazebrook classiﬁcation.
n = Secondary surgery
Needed
High-grade complications
Aseptic loosening 8 8 
Deep  infection 4 4 
Implant failure (bearing dislocation) 3 3 
Idiopathic pain 5 5 
Medium-grade complications
Implant subsidence 6 6 
Postoperative fracture 1 0 
Technical error 4 0 
Impingement 15 15 
Low-grade complications
Intra-operative fracture 1 0 
Delayed wound healing 6 0 
AR: total ankle replacement. 30 (left) and last 30 (right) TAR implants.
at 47.2, 56.2 and 92.5 months, respectively (Fig. 10). The CT scan
analysis is summarized in Table 4.
Since Type A cysts were most common (93% of all cysts found),
sub-groups were created (Table 5). In 80% of cases, these cysts
were smaller than 100 mm2 (Fig. 11). The risk of cysts appearing
under the talar component was  signiﬁcantly greater for cemented
implants or when the talar component was improperly positioned
(P < 0.05). There was  no statistical relationship between the risk of
cysts appearing and the presence of a tibial keel (P = 0.79).
Fusion
Needed
Average time elapsed (months) between
TAR and secondary procedure
8 40.5 [11.3–81.9]
2 n < 5
0 n < 5
5 43.5 [25.1–64.1]
0 40.2 [18.9–98.9]
0 X
0 X
0 22.5 [6.7–56]
0 X
0 X
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Fig. 9. Ankle joint range of motion on radiographs.
Table 2
Location of cysts on the radiographs.
Location of cysts 1 year 2 years 5 years 7 years
A (%) B (%) C (%) A (%) B (%) C (%) A (%) B (%) C (%) A (%) B (%) C (%)
Tibial component
Zone 1 0 0 0 2.6 0 0 2.8 0 0 7.4 0 0
Zone  2 0 0 0 0 0 0 0 0 0 0 0 0
Zone  6 0 0 0 0 0 0 0 0 0 0 0 0
Zone  7 0 0 1.8 0 0 2.6 0 0 0 3.7 0 0
Talar  component
Zone 5 0 0 0 0 0 0 0 0 0 0 0 0
Zone  8 0 0 1.8 0 0 0 0 0 0 0 0 0
Zone  9 0 0 3.6 0 0 0 0 2.8 0 0 0 0
Table 3
Characteristics of bone-implant interface based on radiographs.
Talus Tibia
Bone-implant 1 year 2 years 5 years 7 years 1 year 2 years 5 years 7 years
Normal 53 (96%) 39 (100%) 34 (97%) 27 48 (87%) 34 (87%) 32 (92%) 24 (88%)
RLL  (≤ 2 mm) 0 0 0 0 6 (11%) 4 (10%) 2 (4%) 1 (3%)
Small  cyst 0 0 0 0 0 0 1 (2%) 2 (6%)
Type  A cyst (3–5 mm)
Medium cyst 0 0 1 (3%) 0 0 0 0 0
Type  B cyst (> 5 mm to 1 cm)
Large cyst 2 (4%) 0 0 0 1 (2%) 1 (3%) 1 (2%) 1 (3%)
Type  C cyst (1–2 cm)
Massive cyst 0 0 0 0 0 0 0 0
Type  D & E cyst (> 2 cm)
RLL: radiolucent lines.
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Table 4
Characteristics of bone-implant interface based on CT scans (42 scans/44 TAR).
Number & size
of cysts
Location
Talus: head Talus: body Tibia med  Tibia lat Fibula
A (< 200 mm2) 8 16 15 5 7
1  or 2
> 2 6 1
B  (200–400
mm2)
1 or 2 1 2 1
>  2
C (> 400 mm2)
T
Dig. 10. Example of CT scan after 8 years showing a talar cyst greater than 200 mm2
n size on a cemented implant.
. DiscussionThis study demonstrates that CT scans are better than radio-
raphs at detecting bone cysts. Cysts were found near 50% of tibial
omponents (all type A) and 57% of talar components (93% type A).
imitations of this study revolve around its retrospective design
able 5
istribution of Type A cysts found on CT scans.
Location Volume 
0–50 mm2 50–100 mm2
Talus: head 5 1 
Talus: body 6 15 
Tibia  med  2 9 
Tibia  lat 4 1 
Fibula 2 4 
Fig. 11. Type A cyst that is s1 or 2
> 2
and the number of patients lost to follow-up, although most of the
cases in this study (97.7% of in situ implants) were evaluated by CT
scan.
4.1. Clinical and functional outcomes
The medium-term clinical and functional results in the current
study are similar to the ones for other mobile-bearing TAR implants,
which had between 70% and 98% survivorship at 3–6 years [15–17].
The signiﬁcant increase in the AOFAS score and the survival curves
are similar to those of studies not involving the implant designers
and to results of national registers [18,19]. The outcomes in the
current study were all evaluated by independent raters who had
not been involved in the surgery or implant design.
Total A
100–150 mm2 150–200 mm2
1 1 8
1 22
3 2 16
5
1 7
maller than 100 mm2.
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The main cause of revision was impingement at the malleolar
rooves, which we added to the Glazebrook’s list of medium-grade
omplications [14,20]. The current study conﬁrms the learning
ffect with this implant, as there were fewer revisions in the sur-
eons’ later cases [21]. The presence of idiopathic pain was also
dded to the list of high-grade complications.
.2. Radiological outcomes
The appearance of cysts and osteolysis around TAR implants in
he medium and long-term has contributed to CT scanning being
ptimal imaging modality for following TAR implants. Mapping of
he periprosthetic areas is now routine [11,22]. One of this study’s
trengths lies in the large number of postoperative CT scans that
ere performed. Our results conﬁrm the ﬁndings of other teams
hat such an analysis is best at evaluating and quantifying any cystic
steolysis, which is underestimated by radiographs [4,23,24]. The
hree cases with a cyst larger than 200 mm2 occurred in cemented
alar implants. Our ﬁndings indicate that the risk of osteolysis is
igniﬁcantly larger with cemented implants. We  have since stopped
ementing TAR implants, unless the bone quality is so low that
he surgeon believes the implants will have poor primary stability.
he vast majority of the cysts identiﬁed in the current study were
maller than 200 mm2; 80% were smaller than 100 mm2 and were
ound under the talar component or on the medial side of the tibia.
Although we cannot explain why there were no large cysts,
e suspect that the AKILETM implant’s design and composition
ikely had an effect, suggesting a potential advantage associated
ith CarbioceramTM. Unlike other TAR models which are made of
obalt-chrome, the AKILETM implant is manufactured from high
itrogen stainless steel and coated with CarbioceramTM. The hard-
ess of this diamond-like carbon reduces the friction coefﬁcient and
roduction of polyethylene or metal wear debris that causes oste-
lysis [25,26]. Cobalt-chrome particles seem to be the most toxic
or osteoblasts and ﬁbroblasts [27,28]. Titanium is typically used in
mplants because it is fully biocompatible, non-allergic and resists
orrosion, but its lack of hardness triggers the release of micro-
articles. A large amount of titanium and cobalt-chrome particles
ave been observed in periprosthetic tissues [29,30]. These inter-
ere with osteoblast function and stimulate osteoclasis [31–33]. In
he AKILETM implant, the bone-implant interface consists of alu-
ina instead of hydroxyapatite and porous titanium. The alumina
oating interferes less with homeostasis because it is biologically
nert and provides good bone integration [34–36].
. Conclusion
The AKILETM implant is unique in its design (spherical tibial
mplant, dual-curvature mobile-bearing), composition (stainless
teel implants with a CarbioceramTM ceramic coating) and ﬁxa-
ion through an alumina coating. The combination of these features
as led to clinical outcomes that are similar to other TAR implants.
owever, fewer and smaller periprosthetic cysts were found in the
edium-term, which should improve stability in the long-term. At
his point, we are not able to isolate which of these factors is the
ost important. Implementation of a national TAR registry would
e very valuable because only long-term follow-up of large cohorts
as the ability to bring together multiple factors and to answer
ome of the questions surrounding total ankle arthroplasty.isclosure of interest
DC: Sporadic involvement (consulting for I.CERAM).
OL: Sporadic involvement (consulting for I.CERAM).
[logy: Surgery & Research 100 (2014) 907–915
JL-H, ET, VD declare that they have no conﬂicts of interest con-
cerning this article.
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